{"ticker": {"uuid": "59f06bf4-da43-43f2-b3bf-66f00bd19b6e", "symbol": "SYNACT", "name": "SynAct Pharma AB", "exchange": "STO", "country": "SE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "SynAct's resomelagon shows promising results in osteoarthritis", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTnJTWHNaQXhOTFFZdng3Y0toWlc5ZnlPMmNNbFNoZHVab3VkaG15MW1qVnZhZjFENUpWYS11WjRZYU1aQUdSSlVfTU5vbUlPeW5UM3BnVG0yWVV5ZUp1aU9FbDYyVjRjcEJCcktuREZ4OWNEWlZHM0RpUTlsQy1mdWpNNnliMkpsRVdYcnd3?oc=5", "source_name": "Biostock", "published_at": "2026-07-10T11:42:56+00:00", "published_display": "10 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma: 'Best BIO ever'", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1mVk0xMWhNR1dMeUp3WC1xT0dGRkY4c2NaenBwX0dhRF9xcEs5RjFJTjV5djNlS2owOWRYd1pDekQ3aE9NX1BMQnZFdHVZOHVhT1lNN2ROZHdhQVVjemdfSWE1ajJmYW9DdTcw?oc=5", "source_name": "Biostock", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech cashes up, SynAct narrowly misses \u2013 the Nordic Pulse | 2026:25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1aX0ZhamdOclJxbldtS19tMnpzd2cwOC1MNWE5dzJkcS1qQWxLTXhYMDJ3b3pLMlMzVmRaajlfWWtnWTZIX3RMYmE5Q1gyRlR6TTZxcXBkVnAtalZxTFUwOXZDc2xoZw?oc=5", "source_name": "Biostock", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct's CEO comments on the RA study", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFBmVnZHSUNUZFZYWXhOVzRXdDY1d3VvNDZzRzJjVmp0ZmRIenFTTlVlT2l3Qk5vS08wallFaFRUSDNUZWJXa0NVN0ZLYno5ZVNaVVY5Ti1lR25LMHJDakFWb2lCem5TWFZ3NVZQVTNFa0hfWEk?oc=5", "source_name": "Biostock", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct comments on the phase IIb results from ADVANCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPT21lalRfZjNuVnFGcTBhelZLSE9TcENyN1VycFZTS2tpekdfZVYwU3FhdEVWMzJfdk43Nk40Zks2aGJZeGp2bjU1STJvZTE3U014c284VzJDejhTUUpLdkY1TkhVMjk1bmhIV2E5M2pERjg1VURESnYxaW1RWEptYVozOTd1cTRCdmc?oc=5", "source_name": "Biostock", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SynAct Pharma (STO:SYNACT) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQekNFam50eF9YdklWbkE2U3pxT0Q2NTJqQUF0dTlHTDhuaUdzRi1tWDduMjdJSVNYb1cyWFJDX251RmhFWVBPak9ab09QRXp2d2RHVlQycmt4SXlpYk0xSzRSVko3UXR5ZHpsNkllS1VyNF96dldXelBCX2lrNUZ5R1JDNHlMend1MkZIVTV6dllDaHd1a2JLcmhRWDZjamUxaC0yX3gyY0tJd0tGSk5nVnF0UGxzekJwWTlDd0dYOERMT3EzWnRBMWVFbWFHN2lJ?oc=5", "source_name": "Biostock", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What good data looks like: SynAct Pharma ahead of its ADVANCE readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNU5pVWwtR1lrd3laOG5xaVBHWk1QeDJXaG5DcUtkazdiWnJPLW53TDJKT0pVbWtSQXBsWnpwTy1HQi1LRmEtQTlmUm1zNHVUNTBsWDBlOHE4QXBiLXQ2ZlJ0QmpjTUtjOEh6bTcxVXhzYktJdzZEZW5xRC1PV3NUX1d1Z2kteEpvaElz?oc=5", "source_name": "Biostock", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma secures 51,9 million SEK to strengthen clinical runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPMWJGY09DejlieDdwN0FEc01qdVlMVnFmTkNDaEM0QjhnM0M1OW1hemFHRVB0cVB6alFDMFBSaFNRN2p4WWNGQlNCQ1E2aDFyWmI2by1Hbm9KMzlzWEtyOG1DMThqeEFKNjR4RXJxM0FZMUgyOFkyOEhSaER6WnpKeVJhOEZ3NDMwQWZPa2tyVQ?oc=5", "source_name": "Biostock", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Topline results on the horizon for SynAct Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE54bk9yWFBZWjNuelJaYUxYeU01XzJpQlRTc3RhZU41VTZMUXdqUlZ2VUZWLU5CQldKUkNPQld6TFp6MWdocVN6Y2ZLNjk1TnAwQXdSRlpqaUZCeFlYQkVuSFd0ZjlSNk5CQ1JpNHVHNHFwZjJHNy00bVdodnptVVE?oc=5", "source_name": "Biostock", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma on its dual strategy, partner interest and commercial potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTmR1MFRZWlNZdGZuSGM0LXdFUC1RYkxuUTl4azB0UDcwQlEwa2dMTWdfTmxpZEV3N0k1NjdaMnA1LXpFUzlBS3NmT2ZPNEluWlluN1VvWmQ3bWI3SW92amtmcktLM1Y4RTdXYjRScUZ4WWhtX3ZrVVFkRUVYYnV2V09DcXVIekhRR1NLYjBTbU1hak5mTnppcnh4dmpiclZMdG1QUm9ETkU?oc=5", "source_name": "Biostock", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma kicks off 2026 ahead of ADVANCE results", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOdVhZRjM4aTcxMkdMQnNaQ3FNY1dxeFZScWpNMTJnZFpKcXdCRmlnYU5CcnozUEJCQmx4ZDNOWC16eWtXRGN6LXhoS05VSlhtdWx5SllVTkNOc2JidE0wNkhVS0h3cEVwOHJIX3JRNDdYSmNUeGkyYXNfR0QzVlFaUUktSEtSRmNyVWR5RkpRMllsY3pR?oc=5", "source_name": "Biostock", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma: \"2026 is going to be a busy year\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPUUV2U2pqZ2tGeTBWczg2c3g1TExLSGxGTlR0WVpJcnRiQ1VZZkJZbEIzZUpCYkN6SVhvd0RGb0FtS0ItNGJiZ2NCaUN5a3k2R3NfeUZjWXZncjdVMkx4Q0VzN1c5MEtaM0xrVGxCNGFhUjZZekc5Y3Fjdk9nSWNudktBdw?oc=5", "source_name": "Biostock", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma's CBO: \u201cWe are pioneering the future of inflammation care\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNbDVoVXRkQV8yTlJVam05RV94cGZ1TzdnZUs0Sk5XMF8xemdGaXJqOUZOTTMtREluejVzbWJkNnJTZmlpakxfSjk5LWxyTmNPMmk3SWtqOGprYTBPS3JRQ2VZQTdYdEdaWjNfeWtZaFpCRkVmMVVkUzgwY0RFcFkxdmZPS21JSXVFeDRCWGZEUUMwSVBVR0VDc0RhRmtUQkFTcGc?oc=5", "source_name": "Biostock", "published_at": "2025-10-10T07:00:00+00:00", "published_display": "10 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma\u2019s Chairman: \u201dWe are confident we have the right strategy\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbW41NDliOHc4M0NoQk5iT0J3cmdXTUxTemd0a09MMjJFcjdUQlNlRWNfVi02dGVTY242dWlJOXpWZDhuYWxRT2hfUWxsanVyc0JPOVk2ak1NLV95S2RXVGdlUGlmeEw0UlFZZzJSSFcyQW5xOXVKdHYwRF9Lb2tFeU5GSld0UnBTQ0hiU1FESWlSVFpVREJUN2hqWEtOZXd3QndGTg?oc=5", "source_name": "Biostock", "published_at": "2025-05-18T16:07:07+00:00", "published_display": "18 May 2025 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma\u2019s CEO provides an update", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9jdF92c2haLVlHMVczdWVDOE5lOU1sSVpwdnJMMWZCeHpabV9uNnpRQm5XeTBmOWdWMEFTZFptQ19KNzEwbTR5QkpoX29LcDlYanl1ZXJmOWFRajJGWWdRMUJfOU1paVVtVHFDRzI1VlJrU2RLakNIVQ?oc=5", "source_name": "Biostock", "published_at": "2025-05-16T03:46:36+00:00", "published_display": "16 May 2025 03:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep dive into SynAct Pharma\u2019s new strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPOUU1RFBpQUg3WjcxQWpZSnU1dW9Ca0czdTZXVkY4SHhwTVJMVm8zZkkwa1F3VDJiRkdnalB0dnJJdG80dTVQTmpacHZWQWFzazRzWEdYb0pkb3Q1V0Jld0xtX3o4cEV5ZWZBMXUtR1N4UVp4RTVrQU42YVdvOWRPek5UT1RlaUhP?oc=5", "source_name": "Biostock", "published_at": "2024-02-02T08:00:00+00:00", "published_display": "02 Feb 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Major shareholder in SynAct Pharma requests board change", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxON2ZCV0FQMU9kdVNzVE1sQ3A5dHhQajY3aGsxWWVfVEFwaXl3dVdlQXVUeUllRTZyUktfUlpFSEJwdTItUUx5ZGphbGJsd0d3SFhsM1dBaHRSaFJfSTlCSWRNN2xzazV6TGdXcENuQnkteFFDcjZ5ajgzT1FHbl9KbFRjSl8?oc=5", "source_name": "Biostock", "published_at": "2024-01-29T08:00:00+00:00", "published_display": "29 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma\u2019s CEO comments on EXPAND data", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOaFc3a2ZHQ0RHdEVxRURWZWtLdHJEa0NQR2NZVG4xbmRyNEtvZUJLYzd5czhoUXFFdDVoTG93TjVVMjE5YzZBdkNXdEZBZFVRcGQwRG80OFk3RHFhSVFxa0kzaXRPa250YmZJOUFYT2JJM0hCMHdRbjlha3hVMTZSZVlaVQ?oc=5", "source_name": "Biostock", "published_at": "2023-09-07T07:00:00+00:00", "published_display": "07 Sep 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SYNACT Stock Price and Chart \u2014 OMXSTO:SYNACT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFBMZHVpUFdMSTFfa3hhd3BsVXNTMFhxQTEwN2pBWXZramdpTmp4RWpGdlk4bU01UkVNMWRTaUx5N0d6T1NMR2ZzOWxQOVZHSDhKRWV6U0E0TDRxT2tCWFFJ?oc=5", "source_name": "TradingView", "published_at": "2022-07-20T20:55:22+00:00", "published_display": "20 Jul 2022 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "SynAct's resomelagon shows promising results in osteoarthritis", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQTnJTWHNaQXhOTFFZdng3Y0toWlc5ZnlPMmNNbFNoZHVab3VkaG15MW1qVnZhZjFENUpWYS11WjRZYU1aQUdSSlVfTU5vbUlPeW5UM3BnVG0yWVV5ZUp1aU9FbDYyVjRjcEJCcktuREZ4OWNEWlZHM0RpUTlsQy1mdWpNNnliMkpsRVdYcnd3?oc=5", "source_name": "Biostock", "published_at": "2026-07-10T11:42:56+00:00", "published_display": "10 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma: 'Best BIO ever'", "summary": "", "url": "https://news.google.com/rss/articles/CBMia0FVX3lxTE1mVk0xMWhNR1dMeUp3WC1xT0dGRkY4c2NaenBwX0dhRF9xcEs5RjFJTjV5djNlS2owOWRYd1pDekQ3aE9NX1BMQnZFdHVZOHVhT1lNN2ROZHdhQVVjemdfSWE1ajJmYW9DdTcw?oc=5", "source_name": "Biostock", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech cashes up, SynAct narrowly misses \u2013 the Nordic Pulse | 2026:25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE1aX0ZhamdOclJxbldtS19tMnpzd2cwOC1MNWE5dzJkcS1qQWxLTXhYMDJ3b3pLMlMzVmRaajlfWWtnWTZIX3RMYmE5Q1gyRlR6TTZxcXBkVnAtalZxTFUwOXZDc2xoZw?oc=5", "source_name": "Biostock", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct's CEO comments on the RA study", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTFBmVnZHSUNUZFZYWXhOVzRXdDY1d3VvNDZzRzJjVmp0ZmRIenFTTlVlT2l3Qk5vS08wallFaFRUSDNUZWJXa0NVN0ZLYno5ZVNaVVY5Ti1lR25LMHJDakFWb2lCem5TWFZ3NVZQVTNFa0hfWEk?oc=5", "source_name": "Biostock", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct comments on the phase IIb results from ADVANCE", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPT21lalRfZjNuVnFGcTBhelZLSE9TcENyN1VycFZTS2tpekdfZVYwU3FhdEVWMzJfdk43Nk40Zks2aGJZeGp2bjU1STJvZTE3U014c284VzJDejhTUUpLdkY1TkhVMjk1bmhIV2E5M2pERjg1VURESnYxaW1RWEptYVozOTd1cTRCdmc?oc=5", "source_name": "Biostock", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is SynAct Pharma (STO:SYNACT) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxQekNFam50eF9YdklWbkE2U3pxT0Q2NTJqQUF0dTlHTDhuaUdzRi1tWDduMjdJSVNYb1cyWFJDX251RmhFWVBPak9ab09QRXp2d2RHVlQycmt4SXlpYk0xSzRSVko3UXR5ZHpsNkllS1VyNF96dldXelBCX2lrNUZ5R1JDNHlMend1MkZIVTV6dllDaHd1a2JLcmhRWDZjamUxaC0yX3gyY0tJd0tGSk5nVnF0UGxzekJwWTlDd0dYOERMT3EzWnRBMWVFbWFHN2lJ?oc=5", "source_name": "Biostock", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What good data looks like: SynAct Pharma ahead of its ADVANCE readout", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQNU5pVWwtR1lrd3laOG5xaVBHWk1QeDJXaG5DcUtkazdiWnJPLW53TDJKT0pVbWtSQXBsWnpwTy1HQi1LRmEtQTlmUm1zNHVUNTBsWDBlOHE4QXBiLXQ2ZlJ0QmpjTUtjOEh6bTcxVXhzYktJdzZEZW5xRC1PV3NUX1d1Z2kteEpvaElz?oc=5", "source_name": "Biostock", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma secures 51,9 million SEK to strengthen clinical runway", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPMWJGY09DejlieDdwN0FEc01qdVlMVnFmTkNDaEM0QjhnM0M1OW1hemFHRVB0cVB6alFDMFBSaFNRN2p4WWNGQlNCQ1E2aDFyWmI2by1Hbm9KMzlzWEtyOG1DMThqeEFKNjR4RXJxM0FZMUgyOFkyOEhSaER6WnpKeVJhOEZ3NDMwQWZPa2tyVQ?oc=5", "source_name": "Biostock", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Topline results on the horizon for SynAct Pharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE54bk9yWFBZWjNuelJaYUxYeU01XzJpQlRTc3RhZU41VTZMUXdqUlZ2VUZWLU5CQldKUkNPQld6TFp6MWdocVN6Y2ZLNjk1TnAwQXdSRlpqaUZCeFlYQkVuSFd0ZjlSNk5CQ1JpNHVHNHFwZjJHNy00bVdodnptVVE?oc=5", "source_name": "Biostock", "published_at": "2026-02-20T08:00:00+00:00", "published_display": "20 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma on its dual strategy, partner interest and commercial potential", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOTmR1MFRZWlNZdGZuSGM0LXdFUC1RYkxuUTl4azB0UDcwQlEwa2dMTWdfTmxpZEV3N0k1NjdaMnA1LXpFUzlBS3NmT2ZPNEluWlluN1VvWmQ3bWI3SW92amtmcktLM1Y4RTdXYjRScUZ4WWhtX3ZrVVFkRUVYYnV2V09DcXVIekhRR1NLYjBTbU1hak5mTnppcnh4dmpiclZMdG1QUm9ETkU?oc=5", "source_name": "Biostock", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma kicks off 2026 ahead of ADVANCE results", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOdVhZRjM4aTcxMkdMQnNaQ3FNY1dxeFZScWpNMTJnZFpKcXdCRmlnYU5CcnozUEJCQmx4ZDNOWC16eWtXRGN6LXhoS05VSlhtdWx5SllVTkNOc2JidE0wNkhVS0h3cEVwOHJIX3JRNDdYSmNUeGkyYXNfR0QzVlFaUUktSEtSRmNyVWR5RkpRMllsY3pR?oc=5", "source_name": "Biostock", "published_at": "2026-01-02T08:00:00+00:00", "published_display": "02 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma: \"2026 is going to be a busy year\"", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPUUV2U2pqZ2tGeTBWczg2c3g1TExLSGxGTlR0WVpJcnRiQ1VZZkJZbEIzZUpCYkN6SVhvd0RGb0FtS0ItNGJiZ2NCaUN5a3k2R3NfeUZjWXZncjdVMkx4Q0VzN1c5MEtaM0xrVGxCNGFhUjZZekc5Y3Fjdk9nSWNudktBdw?oc=5", "source_name": "Biostock", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma's CBO: \u201cWe are pioneering the future of inflammation care\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNbDVoVXRkQV8yTlJVam05RV94cGZ1TzdnZUs0Sk5XMF8xemdGaXJqOUZOTTMtREluejVzbWJkNnJTZmlpakxfSjk5LWxyTmNPMmk3SWtqOGprYTBPS3JRQ2VZQTdYdEdaWjNfeWtZaFpCRkVmMVVkUzgwY0RFcFkxdmZPS21JSXVFeDRCWGZEUUMwSVBVR0VDc0RhRmtUQkFTcGc?oc=5", "source_name": "Biostock", "published_at": "2025-10-10T07:00:00+00:00", "published_display": "10 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma\u2019s Chairman: \u201dWe are confident we have the right strategy\u201d", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbW41NDliOHc4M0NoQk5iT0J3cmdXTUxTemd0a09MMjJFcjdUQlNlRWNfVi02dGVTY242dWlJOXpWZDhuYWxRT2hfUWxsanVyc0JPOVk2ak1NLV95S2RXVGdlUGlmeEw0UlFZZzJSSFcyQW5xOXVKdHYwRF9Lb2tFeU5GSld0UnBTQ0hiU1FESWlSVFpVREJUN2hqWEtOZXd3QndGTg?oc=5", "source_name": "Biostock", "published_at": "2025-05-18T16:07:07+00:00", "published_display": "18 May 2025 16:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma\u2019s CEO provides an update", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE9jdF92c2haLVlHMVczdWVDOE5lOU1sSVpwdnJMMWZCeHpabV9uNnpRQm5XeTBmOWdWMEFTZFptQ19KNzEwbTR5QkpoX29LcDlYanl1ZXJmOWFRajJGWWdRMUJfOU1paVVtVHFDRzI1VlJrU2RLakNIVQ?oc=5", "source_name": "Biostock", "published_at": "2025-05-16T03:46:36+00:00", "published_display": "16 May 2025 03:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep dive into SynAct Pharma\u2019s new strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxPOUU1RFBpQUg3WjcxQWpZSnU1dW9Ca0czdTZXVkY4SHhwTVJMVm8zZkkwa1F3VDJiRkdnalB0dnJJdG80dTVQTmpacHZWQWFzazRzWEdYb0pkb3Q1V0Jld0xtX3o4cEV5ZWZBMXUtR1N4UVp4RTVrQU42YVdvOWRPek5UT1RlaUhP?oc=5", "source_name": "Biostock", "published_at": "2024-02-02T08:00:00+00:00", "published_display": "02 Feb 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Major shareholder in SynAct Pharma requests board change", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxON2ZCV0FQMU9kdVNzVE1sQ3A5dHhQajY3aGsxWWVfVEFwaXl3dVdlQXVUeUllRTZyUktfUlpFSEJwdTItUUx5ZGphbGJsd0d3SFhsM1dBaHRSaFJfSTlCSWRNN2xzazV6TGdXcENuQnkteFFDcjZ5ajgzT1FHbl9KbFRjSl8?oc=5", "source_name": "Biostock", "published_at": "2024-01-29T08:00:00+00:00", "published_display": "29 Jan 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SynAct Pharma\u2019s CEO comments on EXPAND data", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOaFc3a2ZHQ0RHdEVxRURWZWtLdHJEa0NQR2NZVG4xbmRyNEtvZUJLYzd5czhoUXFFdDVoTG93TjVVMjE5YzZBdkNXdEZBZFVRcGQwRG80OFk3RHFhSVFxa0kzaXRPa250YmZJOUFYT2JJM0hCMHdRbjlha3hVMTZSZVlaVQ?oc=5", "source_name": "Biostock", "published_at": "2023-09-07T07:00:00+00:00", "published_display": "07 Sep 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SYNACT Stock Price and Chart \u2014 OMXSTO:SYNACT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTFBMZHVpUFdMSTFfa3hhd3BsVXNTMFhxQTEwN2pBWXZramdpTmp4RWpGdlk4bU01UkVNMWRTaUx5N0d6T1NMR2ZzOWxQOVZHSDhKRWV6U0E0TDRxT2tCWFFJ?oc=5", "source_name": "TradingView", "published_at": "2022-07-20T20:55:22+00:00", "published_display": "20 Jul 2022 20:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 76, "total_relevant": 20, "sentiment_summary": {"positive": 1, "negative": 1, "neutral": 18, "score": 50, "total": 20, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 8.8, "count": 16}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}], "positive_events": 1, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 21.8, "latest_week": "2026-07-10", "one_week_move": 15.2, "four_week_move": 50.3, "twelve_week_move": 27.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.340257, "market_dynamics_buy_signal": false, "relative_strength": 1.582811, "fair_value_gap": 20.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.825, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+15.2% over one week, +50.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Biostock", "count": 18}, {"label": "simplywall.st", "count": 1}, {"label": "TradingView", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 20}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 16}, {"label": "Earnings", "count": 4}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "20", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+15.2% over one week, +50.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "SynAct's resomelagon shows promising results in osteoarthritis"}], "updated_at": "2026-07-17T20:37:07.584952+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}